



The Digital Examiner www.prostaid.org

“Issue #307” July 2025

YAHOO!!!!



JULY 2025

Upcoming Events



***Mark This Date & Come And Join Us For Our 3rd
Annual Picnic On July 16th
At The CKE Community Hall
Starts at 6pm
This is for all our Warriors, Wives
Partners, Caregivers and their families.
Watch your email inbox for your invitation.***

**Starting July 16th, our progressive 50/50 raffle
will run each month and the final draw will be
held at our 2025 Pathfinder Award event in
December. Our mission is to support all of our
ongoing Community events.**



This will be a 6 month consecutive sales of tickets at all of our General meetings. You must buy a ticket in person at one or all of these meetings. All tickets sold will be recorded so that if for any reason your unable to attend the final draw, you will still be eligible. We will have an electronic paying option as well as cash. The ticket price is 1 for \$5 or 3 for \$10.

**THERE WILL BE NO ONLINE SALES AT ALL ONLY IN PERSON SALES AND
ALL SALES ARE FINAL**

AGLC Licence# 733539



Warriors Lunch

Reminder to all of our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for **Tuesday August 5th** starting at 11:30 am.

Confirm your attendance and don't forget to bring \$20 to help cover the cost.

RSVP info@prostaid.org

Bella Roma Pizza #17 6449 Crowchild Tr. SW.

Next General Meeting will be August 20th with Chelsea Anderson

All of our monthly General meetings are in person or via Zoom

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB

If you are unable to attend in person you can always join us via
Zoom please sign up [HERE](#)

Warriors & Wives Partners and Caregivers

Join us on Wednesday, August 20th. We are meeting at CKE starting at 6:00 pm with a social gathering in the lounge and separate meetings from 6:30 to 7:30 prior to the general meeting in the main hall.

We are in Urgent Need of a Vice President.

You can play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future.

We will help you grow into this position and "If you believe this is the perfect opportunity for you, we'd love to hear from you

Reach out to any of our Board members or connect with me directly at program.director@prostaid.org.



Donate Today

PROSTATAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

Connect With Us

Information
Phone 403 455 1916
info@prostaaid.org
Brad Sterling
President
president@prostaaid.org

[Connect With Us](#)

Support Groups

Jim Richardson
Warriors
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaaid.org

[Meeting Info Here](#)

Articles Of Interest




DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 50 to 70 years of age

- No appointment necessary
- Testing ages 40 to 80
- Find the next community clinic near you
- 15 minutes can save your life!

[MAN VAN UPCOMING CLINICS](#)




Study shows the glucocorticoid receptor is a double-edged sword in prostate cancer

Steroid receptors also include the androgen receptor, the hyperactivity of which is the main factor contributing to the pathogenesis and progression of prostate cancer. Therefore, androgen receptor inhibition is the primary goal of drug therapy targeting prostate cancer, but prostate cancer can also become resistant to such therapies. This resistance is often facilitated by the glucocorticoid receptor, which can replace the androgen receptor and become a cancer-promoting factor itself.

More Trial Info

June 2025
MedicalXpress

Glucocorticoid



Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

The COMRADE study (NCT03317392) was a phase 1/2 study. In phase 1, the recommended phase 2 dose of olaparib of 200 mg twice daily was established, along with fixed dose radium-223 at 55 kBq/kg every 4 weeks for up to 6 doses.

In phase 2, patients were randomly assigned in a 1:1 ratio to the combination of olaparib plus radium-223 vs radium-223 alone. The primary end point was investigator-assessed rPFS. Stratification factors included prior docetaxel and extent of bone metastases. Crossover was permitted in the monotherapy arm. All patients required a baseline biopsy and progression biopsy was optional.

June 2025
Cancernetwork

Olaparib/Radium




Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer

The addition of cetrelimab to niraparib maintenance following carboplatin-cabazitaxel (Jevtana)-cetrelimab (anti-PD-1) induction led to an improvement in progression-free survival (PFS) and overall survival (OS) in a subset of men with aggressive variant prostate cancer (AVPC), according to data from the phase 2 C3NIRA trial (NCT04592237) presented at the [2025 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#) in Chicago, Illinois.¹

June 2025
Urology Times

Cetrelimab




Clinical trial shows biomarkers hold clue in treating aggressive prostate cancer

The pilot trial (NCT04030559) looked at whether giving the [PARP inhibitor](#) niraparib before surgery could help prevent cancer from returning in men with [aggressive prostate cancer](#).

A total of 11 men with high-risk prostate cancer and certain biomarkers, specifically gene mutations, took part in the study. Each patient received 200 mg of niraparib daily for 90 days before undergoing surgery.

June 2025
Oncology & Cancer

Aggressive



Study delves into the complexity of the most aggressive form of prostate cancer


Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we now call precision oncology, characterizing the molecular features of a patient's specific cancer to determine the most effective treatment.

Prostate cancer is considered the most prevalent tumor among men, and it typically has a high cure rate. As such, although many men will be diagnosed with this cancer, the majority will be cured.

[More Info Here](#)

May 2025
MedicalXpress

Study




FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

The FDA has accepted a supplemental new drug application (NDA) for talazoparib (Talzenna) plus enzalutamide (Xtandi) in patients with homologous recombination-repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (CRPC), according to a news release from the drug's developer, Pfizer Inc.

[Trial Updates](#)

June 2025
Cancernetwork

sNDA




Real-world studies compare overall survival between ARPIs in mCSPC

Although androgen receptor pathway inhibitors (ARPIs) are widely used in clinical practice for patients with metastatic castration-sensitive prostate cancer (mCSPC), there are no head-to-head trials comparing their efficacy. This means that treatment selection comes down to patient-specific factors such as comorbidities, potential drug-drug interactions, and other considerations.

Trial Results

June 2025
Urology Times

Real-world




CAN-2409 Immunotherapy Shows Efficacy for Intermediate-, High-Risk Prostate Cancer

CAN-2409, an adenoviral vector, plus prodrug kills tumor cells and stimulates a cancer vaccine effect in men with localized intermediate- to high-risk prostate cancer reducing the risk for disease recurrence or death compared with placebo, a phase 3 trial finds.

Trial Results

June 2025
Renal+Urology

CAN -2409



ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

ClarityDX


Read about these articles below

- 1-Exercise during chemotherapy**
- 2-Acupuncture may alleviate nocturia**
- 3-Prostate Biopsy Warrant Concern**
- 4-Overcoming Barriers to Genetic Testing**
- 5-Urinary urge incontinence**
- 6-Scientists develop AI method to predict overall survival rate**
- 7-Artificial intelligence is the new electricity**
- 8- Multivitamins May Have Lower Risk of Recurrence**
- 9-Canadian Prostate Cancer Guide**
- 10-Unnecessary cancer screenings continue years after guidelines change**

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



Articles For Everyone




Exercise during chemotherapy may help immune cells fight cancer

There have been a number of animal-based studies showing that exercise can improve immune responses and reduce cancer growth. However, previous studies in humans—mainly focused on prostate or colorectal cancer—have not shown a clear increase in tumor-infiltrating immune cells after exercise, even after multiple sessions.

June 2025
MedicalXpress

Chemotherapy



Acupuncture may alleviate nocturia in men treated for prostate cancer

Kevin T. Liou, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a randomized trial to evaluate acupuncture (10 weekly standardized treatments) relative to usual care for nocturia in prostate cancer survivors. The analysis included 60 participants treated with prostate cancer who reported two or more nocturia episodes every night for the past month.

June 2025
MedicalXpress

Acupuncture



Grade Group 1, ASAP Found on Prostate Biopsy Warrant Concern

“There is current controversy whether Grade Group (GG) 1 should be designated as ‘cancer,’ as studies demonstrate that it does not metastasize, and active surveillance is the standard of care,” Dr Wang’s team stated. “Although we are unable to adjust for the use of biomarkers such as MRI and genomic testing which improve risk stratification, our findings do not support disassociating ‘cancer’ from GG1 prostate cancer.”

Study Details

June 2025
Renal + Urology News

Biopsy



Overcoming Barriers to Genetic Testing in Prostate Cancer Care

Germline genetic testing is currently recommended by the National Comprehensive Cancer Network for all patients with metastatic, regional (node-positive), high-risk localized, or very high-risk localized prostate cancer as well as for individuals with specific family histories of cancer or Ashkenazi ancestry. patient.

[More Info Here](#)

May 2025
JCO Oncology Practice

Genetic



FDA approves integrated sacral neuromodulation system for urinary urge incontinence

- Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UII patients.
-
- The SANS-UII trial showed 84.2% of patients achieved at least a 50% reduction in urgent leaks, with significant quality of life improvements.

June 2025
Urology Times

Incontinence



Scientists develop AI method to predict overall survival rate of prostate cancer patients

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates of patients afflicted with prostate adenocarcinoma, which is by far the most common type of prostatic cancer cases.

June 2025
MedicalXpress

Machine learning



Artificial intelligence is the new electricity

In this issue of *BOB Tales*, we look at four powerful new tools that use AI to detect cancer earlier, more accurately, and far less invasively. From urine tests that outperform PSA to an AI model that stages cancer better than MRI—there's even an AI-powered test that can detect more than 50 types of cancer from a single blood draw.

June 2025
Bob Tales

AI



Prostate Cancer Patients Who Take Multivitamins May Have Lower Risk of Recurrence

At a median of 28 months after diagnosis, the patients completed a questionnaire that asked about multivitamin use after diagnosis and before recurrence. Sixty-two percent of patients reported being current multivitamin users, 16% reported prior multivitamin use, and 22% reported never using multivitamins.

[More Info Here](#)

May 2025
Cancernetwork

Multivitamins

Canadian Prostate Cancer Guide

Resources, guides and tools to help caregivers, survivors and the recently diagnosed get clarity and more. Read empowering stories and share yours with us.

Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

[Learn More Here](#)



Unnecessary cancer screenings continue years after guidelines change, study finds

"Excessive screening opens the door for a lot of negative consequences," said Jennifer LeLaurin, Ph.D., an assistant professor of health outcomes and [biomedical informatics](#) at the University of Florida and lead author of the new study. "These guidelines are based on what the benefits and harms are. If the harms outweigh the benefits for a particular test, then they recommend against it."

June 2025
Oncology & Cancer

[Unnecessary](#)

Thank you to our Sponsors and Community Partners



Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on

PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)